FSD201

DRUG2 trials

Sponsors

Quantum Biopharma

Conditions

COVID-19Mast Cell Activation Disorder IdiopathicMast Cell Activation Syndrome

Phase 2

Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

TerminatedNCT04619706

Quantum BiopharmaCOVID-19

Start: 2020-12-14End: 2021-08-24Updated: 2022-12-05

Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

TerminatedNCT05652907

Quantum BiopharmaMast Cell Activation Disorder Idiopathic, Mast Cell Activation Syndrome

Start: 2023-01-19End: 2023-05-24Updated: 2026-04-21

Related Papers

Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor

Viruses2022-05-1730 citations